Skip to main content

Table 4 HSUVs associated with CRC treatments and AEs

From: Systematic review of health state utility values for economic evaluation of colorectal cancer

Reference Valuation methods used HSUVs
Bennett [56] EQ-5D 1st line
Panitimumab + FOLFOX4 0.778; FOLFOX4 0.756
2nd line
Panitimumab + FOLFIRI 0.769; FOLFIRI 0.762
Best [4] TTO CRC patients/community members
Remission 0.83/0.82
adjuvant, no neuropathy 0.61/0.60
adjuvant, mild neuropathy 0.61/0.51
adjuvant, moderate neuropathy 0.53/0.46
adjuvant, severe neuropathy 0.48/0.34
metastatic, stable 0.40)/0.51
metastatic, progressive 0.37/0.21
Dranitsaris [48]b TTO FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–33 months] 0.68-0.89
FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.70-0.94
Dranitsaris [36]b TTO FOLFOX±’new drug’ → FOLFIRI → BSC until death [2–29 months] 0.67-0.83
FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.72-0.91
Dranitsaris [48]b TTO FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–29 months] 0.52-0.84
FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.53-0.84
Dranitsaris [36]b TTO FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–28 months] 0.44-0.72
FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.44-0.71
Farkkila [51] EQ-5D Metastatic disease 0.820
Palliative care 0.643
Mittmann [38]b HUI3 Cetuximab + BSC 0.71-0.77
BSC 0.66-0.71
Odom [58] EQ-5D Panitumumab plus BSC; BSC alone
Overall 0.72; 0.68
Wild-type KRAS 0.73; 0.68
Mutant KRAS 0.71; 0.68
Petrou [20]a SG Partial response 1.0
Stable disease 0.95
Progressive disease 0.575
Terminal disease 0.1
Shiroiwa [44] TTO XELOX without AEs 0.59
FOLFOX without AEs 0.53
Febrile neutropenia 0.39
Nausea/vomiting 0.38
Diarrhoea 0.42
Hand-foot syndrome 0.39
Fatigue 0.45
Peripheral neuropathy 0.45
Stomatitis 0.42
Wang [60] EQ-5D Panitumumab + BSC; BSC
TOX 0.6008; 0.4409
TWiST 0.7678; 0.6630
REL 0.6318; 0.6407
Wiering [29] EQ-5D Disease-free 0.78
non-curative 0.67
recurrence 0.74
recurrence with chemotherapy 0.82
Recurrent without chemotherapy 0.68
Ward [14] EQ-VAS Capecitabine and bevacizumab
Baseline 61.76 (SD 23.15)
Cycle 2 68.59 (SD 22.26) [p = 0.06]
End of study 66.54 (SD 23.18) [p = 0.29]
  1. aReported HSUVs are re-expressed on a 0–1 scale
  2. bRanges of reported HSUVs
  3. AE adverse event, BSC best supportive care, FOLFOX Oxaliplatin + infusional 5 fluorouracil (5-FU), FOLFIRI Irinotecan + infusional 5 fluorouracil (5-FU), FOLFOX4 5-fluorouracil/folic acid and oxaliplatin, HSUVs health state utility values, KRAS Kirsten rat sarcoma viral oncogene, REL (relapse period until death or end of follow-up), SD standard deviation, SG Standard gamble, TOX days with ≥ grade 3 adverse events, TTO time trade-off, TWiST time without symptoms or toxicity, XELOX capecitabine plus oxaliplatin